Introduction Methods
Captopril added to human plasma Experimental investigations have suggested that captopril may exert some beneficial effects in the clinical setting as a result of its thiol group-related antioxidant Reagents were from Sigma Aldrich s.r.l., Milano, Italy. Heparinized plasma was obtained from seven male properties [1] [2] [3] . In this regard, captopril has been shown to scavenge efficiently only hydroxyl radical healthy adults (35-45 years old). We at first investigated whether captopril, added to (OHΩ) and hypochlorous acid (HOCl ) [3 ] . It must be noted, however, that high captopril concentrations and human plasma at therapeutically relevant concentrations, could augment antioxidant properties of plasma aqueous buffers in the absence of biomolecules present in the blood environment in vivo have usually been used itself against OHΩ-and HOCl-induced oxidant injury. Regarding OHΩ, it is known that this oxygen radical to study captopril antioxidant effects in vitro. These biomolecules, such as albumin, can readily react with is also generated via Fenton chemistry reactions in the presence of EDTA-complexed iron, H 2 O 2 and ascorbate OHΩ and HOCl [4, 5] . Thus, it seems relevant for an appropriate evaluation of captopril antioxidant activity as the reducing agent [3] [4] [5] [6] [7] . Once produced, OHΩ can damage oxidatively the sugar deoxyribose (DOR), an to investigate whether the drug is capable of enhancing antioxidant properties of human plasma, as well as of integral component of DNA [4, 5] , producing aldehydic substances capable of reacting with thiobarbituric acid protecting endogenous biomolecules against oxidant aggression and of decreasing systemic oxidant burden (TBA) under acidic conditions [3] [4] [5] [6] [7] . Biological or pharmacological compounds able to scavenge efficiently in humans. These issues have specifically been addressed in the present paper.
OHΩ can counteract OHΩ-dependent DOR oxidation and TBA-reactants (TBA-R) formation [3] [4] [5] [6] [7] . Reaction mixtures (1.0 ml ) contained 10 mmol l−1 potassium phosphate buffer, pH 7.4, 2.8 mmol l−1 DOR, are reached after 1.0 h from drug intake in humans, followed by their rapid and marked decrement [ 10, 11] . 10 mmol l−1 FeCl 3 (pre-mixed with 50 mmol l−1 EDTA), 0.7 mmol l−1 H 2 O 2 and 50 mmol l−1 ascorbic acid, with Systemic oxidative stress status before and after captopril intake was evaluated assessing erythrocyte and without 50 ml of plasma containing or not 10, 50 and 100 mmol l−1 captopril (final drug concentrations and plasma peroxidation, as well as plasma P-SH levels. Erythrocyte peroxidation was assayed basically as were therefore 0.5, 2.5 and 5 mmol l−1 ). After 30 min incubation at 37°C, 1.0 ml−1 of 2.5% trichloroacetic reported by Clot et al.
[12], after reaction of 1.0 ml−1 of the protein-free supernatant resulting from 20% acid (TCA), 1.0 ml−1 of 0.6% TBA aqueous solution and 10 ml of 5% butylated hydroxytoluene (BHT ) in TCA-treated erythrocytes with 1.0 ml−1 of 0.6% TBA aqueous solution. After 30 min heating in the presence ethanol were added, followed by 15 min heating at 95°C. After cooling, the red chromogen, yield of OHΩ-of 15ml of 5% BHT in ethanol, the chromogen was extracted with n-butanol and read at 532 nm against an induced DOR oxidation [3] [4] [5] [6] [7] , was extracted with n-butanol and read spectrophotometrically at 532 nm appropriate blank. Notably, this assay gives results strictly related to those of malonildialdehyde measureagainst an appropriate blank. Results were calculated as nmol TBA-R/mmol DOR, using a molar extinction ment by a direct h.p.l.c. method [ 12] , and it has been pointed out as a valuable index of oxidative stress in coefficient of 154, 000.
Antioxidant effects of control and captopril-containing vivo [ 12] . Plasma lipid peroxidation was studied through the assay of TBA-R, fluorescent damage plasma samples against HOCl were evaluated testing their capability to inhibit HOCl-induced 5-thio-2-products of lipid peroxidation (FDPL) and conjugated dienes (CD). For TBA-R, 0.5 ml−1 aliquots of plasma nitrobenzoic (TNB) oxidation [8 ] . In this context, it is known that the highest oxidant capacity of HOCl is were added to 0.5 ml−1 of 2.5% TCA, 20 m l of 5% BHT in ethanol, 0.1 ml−1 of 8.1% sodium dodecyl explicated against sulphhydryl groups [5, 8, 9] ; the thiol compound TNB, therefore, is readily oxidized by sulphate and 0.5 ml−1 of 0.6% TBA aqueous solution, followed by 30 min heating at 95°C. The chromogen HOCl, this phenomenon being inhibitable by HOCl scavengers [8 ] . TNB was prepared through reduction was then extracted with n-butanol and read at 532 nm against an appropriate blank. FDPL were assessed of 5, 5∞-dithiobis(2-nitrobenzoic acid) (DTNB) with 2-mercaptoethanol [8], and its concentrations were according to Dillard & Tappel [13] , with some modifications. Plasma lipids were extracted with calculated using a molar extinction coefficient of 13, 600 at 412 nm [8 ] . Reaction mixtures (1.0 ml ) contained 6.0 ml−1 of chloroform/methanol (251, vol/vol), followed by 2 min vortex mixing and bi-distilled water addition. 10 mmol l−1 potassium phosphate buffer, pH 7.4, 80 mmol l−1 TNB, 50 ml of plasma with or without After a brief centrifugation, the chloroform phase was dried under a flow of argon gas. The residue was captopril and 33 mmol l−1 HOCl. After 15 min incubation at 25°C, absorbance values at 412 (A 412 ) nm resuspended in cyclohexane and subjected to fluorometric study at 360/430 nm excitation/emission, as well as were read spectrophotometrically, using appropriate plasma-and captopril-containing blanks. The concento ultraviolet spectrophotometric study at 233 nm to assay CD [14 ] . Plasma P-SH represent adequate trations of NaOCl-derived HOCl were calculated by the TNB oxidation method of Thomas et al. 37°C; TBA-R, FDPL and CD were then measured, as described above. Regarding HOCl-mediated plasma years old) of our institutional medical and technical staff were studied twice at a 48 h interval. In the first oxidant damage, 105 mmol l−1 HOCl were added to plasma samples obtained before and after drug intake, day, after plasma and erythrocyte collection for specific biochemical tests in basal conditions, placebo tablets followed by 30 min incubation at 25°C. Since HOCl oxidizes preferentially thiol groups [5, 8, 9] , the loss of were administered orally in the morning in fasting conditions and, after 1 h, blood was collected again to plasma P-SH induced by HOCl was measured spectrophotometrically at 412 nm as described above. repeat the assays. In the second day, the same experimental approach was followed, except that 50 mg captopril tablets (Capoten, Bristol-Myers Squibb S.p.A., Roma, Italy) were administered by mouth; after 1 h, plasma Statistics free captopril levels were also measured essentially as previously reported [10] . In this regard, it must be Data were calculated as means±s.d. The effects of captopril added to plasma were evaluated by the noted that plasma peak concentrations of free captopril one-way analysis of variance plus Student-Newmansignificantly different before and after captopril intake (0.85±0.1 vs 0.87±0.09 nmol TBA-R ml−1 of plasma Keuls test [ 18] . In the experiments performed with blood of subjects taking placebo or captopril tablets, for TBA-R, 24±3. dation (0.56±0.13 vs 0.58±0.12 nmol TBA-R ml−1 of packed cells) and of plasma P-SH (432.5±27 vs 428±25.5 nmol ml−1 of plasma). Captopril intake, therefore, did not result in decreased systemic oxidative Results burden in vivo at drug peak concentrations. Table 2 shows that the copper/H 2 O 2 oxidant system induced a As shown in Table 1 , captopril added to human plasma was incapable of enhancing antioxidant properties of significant increase of plasma TBA-R (P<0.01), FDPL (P<0.01) and CD (P<0.025) with respect to the basal plasma itself against either OHΩ or HOCl.
Plasma drug concentrations were 1.54±0.38 mmol l−1 values; comparable lipid peroxidation levels, however, were observed in the pre-and post-captopril period after 1.0 h from 50 mg captopril tablet intake. At this time, systolic and diastolic blood pressure values fell plasma samples (P=NS; Table 2 ). When plasma was challenged with HOCl, its P-SH content underwent a from 127±5 and 81±5.5 mmHg to 113±4.5 and 69±7.2 mmHg, respectively ( both P<0.01, paired significant decrement (P<0.01), which was about −17 and −18% in the plasma obtained before and after Student's t-test). Since the biochemical data observed in the first 'placebo day' were similar to those of the captopril intake, respectively (P=NS; Table 2 ). second 'drug day', and neither placebo nor captopril affected baseline biochemical data, we will report only the results obtained with captopril administration. Notably, the levels of plasma peroxidation were not Discussion
The present study shows that captopril, at therapeutic operative in various conditions. Blood contains indeed oxidant species reacted preferentially with the endogenous antioxidants, which, although so diluted, had higher strong antioxidant defences, resulting in a high antioxidant capacity [4, 5 ] . For example, albumin reaches concentrations than captopril itself. Moreover, plasma is endowed with several antioxidant defences, which mean concentrations of about 650 mmol l−1 in human plasma, whereas peak plasma levels of captopril are specifically work in a synergic way to cope with oxidant injury. For example, transferrin binds-inactivates cata-0.5-1.5 mmol l−1 in humans after administration of usual drug doses of 25-50 mg [ 10, 11 ] . Moreover, albumin lytic iron, while albumin scavenges OHΩ arising from iron-mediated reactions [ 4, 5] . This synergism of action readily reacts with HOCl [4, 5, 9 ], and is characterized by a second order rate constant for the reaction with appears relevant and amplifies the endogenous antioxidant capacity, besides a mere problem of antioxidant OHΩ of 2.3×1010 mol−1 s−1 [5 ], which is near sevenfold higher than that of captopril, i.e. 3.6×109 mol−1 s−1 concentration. Captopril is characterized not only by very low therapeutic levels [10, 11] , but is also a poor [ 3] . Thus, OHΩ and HOCl react with 650 mmol l−1 albumin and not with 0.5-1.5 mmol l−1 captopril (this thiol donor [21 ] , which does not contribute to plasma antioxidant properties. Thus, for concentration and was exactly the case in our second experimental set). Similar considerations may be done for other physiologikinetic problems, captopril is not an effective scavenging antioxidant in the blood environment. cal plasma antioxidants, such as glucose, ascorbate and uric acid, which reach mean concentrations of 4500, 70
Experimental studies may suggest that captopril could result in some 'indirect-type' antioxidant effects in vivo, and 300 mmol l−1, respectively [ 5] . In this regard, it is noteworthy that plasma uric acid concentrations may potentially due to decreased oxidant generation by neutrophils [ 22] and enhanced production of prostacybe increased in hypertensive patients with or without congestive heart failure, a typical clinical setting of clin [23] , which has antioxidant properties [ 24] . However, our data show that indicators of systemic captopril use in humans [ 20] . The aforementioned biochemical aspects appear relevant also in the case of oxidative stress, such as plasma lipoperoxidation and P-SH, as well as oxidant-driven plasma peroxidation our first set of experiments, where all plasma antioxidants were somewhat 'depleted' because of the 20-fold and P-SH oxidation, are unaffected by captopril intake at peak drug concentrations, pointing to no significant dilution of the 50 ml plasma aliquots in 1.0 ml−1 reaction mixtures. In these conditions, considering only albumin, antioxidant effect of captopril in vivo. Moreover, captopril intake does not affect erythrocyte peroxidation, ascorbate, glucose and uric acid, it may be calculated that their final concentrations in experimental tubes suggesting that also cell systems may not benefit from a putative drug antioxidant activity in vivo. In this context, were about 33, 3.5, 225 and 15 mmol l−1 , respectively, for an 'antioxidant sum' of 276 mmol l−1. Captopril, at it has been shown that the concentrations of free captopril remain virtually unchanged after drug 0.5-5 mmol l−1 concentrations, failed to enhance plasma antioxidant properties against oxidative damage; indeed, incubation with erythrocytes [ 25] , indicating that the enzyme inhibitor captopril to scavenge reactive oxygen thiol group of captopril is not given to cell systems to species. Chem-Biol Interact 1991; 77: 303-314.
enrich their antioxidant potential. 
